Open Questions: Genes

Ranked research questions extracted from wiki pages and knowledge gaps
Field: GenesProteinsMechanismsTherapeuticsDiseasesPathwaysCell TypesBrain RegionsMethods
Sort by: Importance Elo Potential Impact Tractability
200 questions found for field 'Genes'
open ⚖ 1500
Therapeutic window**: When to intervene for maximum benefit?
📑 0.50 💥 0.50
open ⚖ 1500
How do different mutations cause variable phenotypes?
📑 0.50 💥 0.50
open ⚖ 1500
Cell-type specificity**: How does STMN1 function differ across neuron types?
📑 0.50 💥 0.50
open ⚖ 1500
What is the role of SORCS2 in tau pathology propagation?
📑 0.50 💥 0.50
open ⚖ 1500
How do SORCS2 rare variants contribute to disease pathogenesis?
📑 0.50 💥 0.50
open ⚖ 1500
How does PEX16 coordinate peroxisome assembly?
📑 0.50 💥 0.50
open ⚖ 1500
What is the relationship between SORCS2 and other AD risk genes?
📑 0.50 💥 0.50
open ⚖ 1500
Therapeutic windows**: What is the optimal timing for intervention?
📑 0.50 💥 0.50
open ⚖ 1500
What determines the balance between proteasome and autophagy?
📑 0.50 💥 0.50
open ⚖ 1500
Paranodal assembly**: What are the precise molecular events in junction formation?
📑 0.50 💥 0.50
open ⚖ 1500
Can proteasome enhancement slow disease progression?
📑 0.50 💥 0.50
open ⚖ 1500
How does immunoproteasome activity change with normal aging?
📑 0.50 💥 0.50
open ⚖ 1500
Why do certain neuronal populations show vulnerability to proteasome dysfunction?
📑 0.50 💥 0.50
open ⚖ 1500
Therapeutic targeting**: Can lipid droplet pathways be safely modulated?
📑 0.50 💥 0.50
open ⚖ 1500
Disease mechanisms**: How do lipid droplets contribute to neurodegeneration?
📑 0.50 💥 0.50
open ⚖ 1500
Neuronal function**: What is the exact function of PLIN4 in neurons?
📑 0.50 💥 0.50
open ⚖ 1500
Can inhibitory deficits be therapeutically restored?
📑 0.50 💥 0.50
open ⚖ 1500
What determines seizure susceptibility?
📑 0.50 💥 0.50
open ⚖ 1500
How does ZIP11 contribute to zinc dysregulation in neurodegeneration?
📑 0.50 💥 0.50
open ⚖ 1500
What is the precise physiological role of ZIP11 in the brain?
📑 0.50 💥 0.50
open ⚖ 1500
How do specific mutations affect channel function?
📑 0.50 💥 0.50
open ⚖ 1500
Combination therapy**: How does calcium modulation combine with other approaches?
📑 0.50 💥 0.50
open ⚖ 1500
Biomarker potential**: Is CALM4 useful as a disease biomarker?
📑 0.50 💥 0.50
open ⚖ 1500
Cell-Type Specific Function:
📑 0.50 💥 0.50
open ⚖ 1500
Combination therapy
📑 0.50 💥 0.50
open ⚖ 1500
Brain-penetrant activators
📑 0.50 💥 0.50
open ⚖ 1500
Temporal dynamics
📑 0.50 💥 0.50
open ⚖ 1500
Therapeutic targeting
📑 0.50 💥 0.50
open ⚖ 1500
Peripheral blood cells
📑 0.50 💥 0.50
open ⚖ 1500
In Vivo Role
📑 0.50 💥 0.50
open ⚖ 1500
Therapeutic Translation
📑 0.50 💥 0.50
open ⚖ 1500
Precise mechanisms
📑 0.50 💥 0.50
open ⚖ 1500
Cell type specificity
📑 0.50 💥 0.50
open ⚖ 1500
Therapeutic windows
📑 0.50 💥 0.50
open ⚖ 1500
Biomarkers:** Could ZnT3 serve as disease biomarker?
📑 0.50 💥 0.50
open ⚖ 1500
Can biomarkers predict treatment response?
📑 0.50 💥 0.50
open ⚖ 1500
What determines the balance between dominant-negative and loss-of-function?
📑 0.50 💥 0.50
open ⚖ 1500
How does DNAJB7 contribute to synaptic protein homeostasis?
📑 0.50 💥 0.50
open ⚖ 1500
How do genetic variants in ELMO2 contribute to disease risk?
📑 0.50 💥 0.50
open ⚖ 1500
What is the relationship between PRDX2 oxidation and disease progression?
📑 0.50 💥 0.50
open ⚖ 1500
Mechanistic details**: How does CA8 scaffold signaling complexes?
📑 0.50 💥 0.50
open ⚖ 1500
Therapeutic targeting**: How can we achieve selective modulation?
📑 0.50 💥 0.50
open ⚖ 1500
Biomarker potential**: Can RAC1 activity serve as a disease biomarker?
📑 0.50 💥 0.50
open ⚖ 1500
Which ITGAM signaling states are protective (clearance) versus pathogenic (synapse injury)?
📑 0.50 💥 0.50
open ⚖ 1500
How does ITGAM interact with [APOE](/genes/apoe)-[TREM2](/genes/trem2) programs across disease stages?
📑 0.50 💥 0.50
open ⚖ 1500
What is the precise role of neuronal MLCK in AD?
📑 0.50 💥 0.50
open ⚖ 1500
Developmental Regulation**: How does GABRA3 expression change across the lifespan?
📑 0.50 💥 0.50
open ⚖ 1500
Single-cell analysis
📑 0.50 💥 0.50
open ⚖ 1500
Biomarker potential**: Could E2F7 serve as a disease biomarker?
📑 0.50 💥 0.50
open ⚖ 1500
Delivery methods**: How to achieve adequate brain penetration?
📑 0.50 💥 0.50
open ⚖ 1500
Can we selectively inhibit pathogenic while preserving protective functions?
📑 0.50 💥 0.50
open ⚖ 1500
Gene editing
📑 0.50 💥 0.50
open ⚖ 1500
Can it serve as a biomarker for disease progression?
📑 0.50 💥 0.50
open ⚖ 1500
How does ASTN1 switch from migration to synaptic roles?
📑 0.50 💥 0.50
open ⚖ 1500
How does ASTN1 coordinate migration vs. synaptic function?
📑 0.50 💥 0.50
open ⚖ 1500
Which DCTN2 variants reproducibly alter neuronal transport in human systems?
📑 0.50 💥 0.50
open ⚖ 1500
What is the full spectrum of EPG5 substrates in neurons?
📑 0.50 💥 0.50
open ⚖ 1500
Combination Approaches
📑 0.50 💥 0.50
open ⚖ 1500
Biomarker validation**: Is MCCC1 useful for diagnosis?
📑 0.50 💥 0.50
open ⚖ 1500
RAB17-specific regulators
📑 0.50 💥 0.50
open ⚖ 1500
How does cGAS-STING interact with other inflammatory pathways?
📑 0.50 💥 0.50
open ⚖ 1500
Compensatory mechanisms**: What limits therapeutic efficacy of pathway inhibition?
📑 0.50 💥 0.50
open ⚖ 1500
Interaction networks**: What are the complete protein-protein interaction networks?
📑 0.50 💥 0.50
open ⚖ 1500
Therapeutic translation**: Can brain-penetrant Pyk2 inhibitors be developed for clinical use?
📑 0.50 💥 0.50
open ⚖ 1500
How does MAP6 specifically recognize AIS microtubules?
📑 0.50 💥 0.50
open ⚖ 1500
What determines the cold-stable vs. cold-labile microtubule populations?
📑 0.50 💥 0.50
open ⚖ 1500
What resistance mechanisms will emerge?
📑 0.50 💥 0.50
open ⚖ 1500
Disease models**: What are the best cellular and animal models for studying GTF2H2-related neurodegeneration?
📑 0.50 💥 0.50
open ⚖ 1500
Biomarkers**: Could NER capacity or GTF2H2 activity levels serve as biomarkers for neurodegeneration risk?
📑 0.50 💥 0.50
open ⚖ 1500
How is PEX19 expression regulated in different tissues?
📑 0.50 💥 0.50
open ⚖ 1500
Can TNR modulation enhance plasticity in disease?
📑 0.50 💥 0.50
open ⚖ 1500
What are the long-term effects of TNR targeting?
📑 0.50 💥 0.50
open ⚖ 1500
What determines TNR's dual roles in repair and inhibition?
📑 0.50 💥 0.50
open ⚖ 1500
How does TNR interact with other ECM molecules?
📑 0.50 💥 0.50
open ⚖ 1500
What is the optimal therapeutic approach?
📑 0.50 💥 0.50
open ⚖ 1500
Which specific neuronal cell types mediate the effects?
📑 0.50 💥 0.50
open ⚖ 1500
How do EPHA8 effects interact with other AD/PD genetic risk factors?
📑 0.50 💥 0.50
open ⚖ 1500
What determines whether 14-3-3 theta is protective or pathogenic?
📑 0.50 💥 0.50
open ⚖ 1500
Biomarkers**: Are there peripheral markers of TRESK dysfunction?
📑 0.50 💥 0.50
open ⚖ 1500
How can therapeutic window be optimized?
📑 0.50 💥 0.50
open ⚖ 1500
What are the precise molecular mechanisms of SMAD7's neuroprotective effects?
📑 0.50 💥 0.50
open ⚖ 1500
Temporal dynamics**: When is the optimal window for intervention?
📑 0.50 💥 0.50
open ⚖ 1500
Biomarker validation
📑 0.50 💥 0.50
open ⚖ 1500
Mechanism of unique ROBO3 function:** How does ROBO3 signal differently from ROBO1/ROBO2?
📑 0.50 💥 0.50
open ⚖ 1500
Therapeutic windows:** What is the optimal timing for intervention in HGPPS?
📑 0.50 💥 0.50
open ⚖ 1500
Can EPHA1 activation rescue established pathology in late-stage AD?
📑 0.50 💥 0.50
open ⚖ 1500
Biomarker utility**: Is MIEF2 a viable disease marker?
📑 0.50 💥 0.50
open ⚖ 1500
Combination therapy**: Optimal approaches with other targets?
📑 0.50 💥 0.50
open ⚖ 1500
How does RagA specifically regulate local translation at synapses?
📑 0.50 💥 0.50
open ⚖ 1500
What determines tissue-specific patterns of RagA activity?
📑 0.50 💥 0.50
open ⚖ 1500
Can RagA-specific modulators achieve therapeutic benefits without systemic mTORC1 inhibition?
📑 0.50 💥 0.50
open ⚖ 1500
How does NGN2 interact with disease-specific mutations?
📑 0.50 💥 0.50
open ⚖ 1500
Can NGN2 modulation treat neurodegenerative disease?
📑 0.50 💥 0.50
open ⚖ 1500
Can EPHA7 activation rescue established pathology?
📑 0.50 💥 0.50
open ⚖ 1500
What is the optimal therapeutic approach: agonism vs. modulation?
📑 0.50 💥 0.50
open ⚖ 1500
What is the precise molecular mechanism of EPHA7-mediated neuroprotection?
📑 0.50 💥 0.50
open ⚖ 1500
How does CCR8 signaling differ between tissue compartments?
📑 0.50 💥 0.50
open ⚖ 1500
What are the cell-type specific roles of PLIN2?
📑 0.50 💥 0.50
open ⚖ 1500
How is Munc13-2 regulated in different brain regions?
📑 0.50 💥 0.50
open ⚖ 1500
How does autophagy change during normal aging versus neurodegeneration?
📑 0.50 💥 0.50
open ⚖ 1500
What is the relationship between autophagy and apoptosis in neurodegeneration?
📑 0.50 💥 0.50
open ⚖ 1500
Can we develop neuron-specific autophagy modulators?
📑 0.50 💥 0.50
open ⚖ 1500
How is autophagy regulated in different neuronal compartments?
📑 0.50 💥 0.50
open ⚖ 1500
What determines the specificity of cargo recognition?
📑 0.50 💥 0.50
open ⚖ 1500
Disease staging**: What is STMN1's role at different disease stages?
📑 0.50 💥 0.50
open ⚖ 1500
What is the exact mechanism of transport regulation?
📑 0.50 💥 0.50
open ⚖ 1500
Can targeting PEX16 benefit neurodegenerative disease?
📑 0.50 💥 0.50
open ⚖ 1500
What regulates PEX16 expression in different tissues?
📑 0.50 💥 0.50
open ⚖ 1500
Can SORCS2 be targeted therapeutically without adverse effects?
📑 0.50 💥 0.50
open ⚖ 1500
How exactly does SORCS2 modulate APP processing?
📑 0.50 💥 0.50
open ⚖ 1500
Biomarkers**: What indicators predict disease progression or treatment response?
📑 0.50 💥 0.50
open ⚖ 1500
Disease mechanisms**: How do specific mutations lead to diverse phenotypes?
📑 0.50 💥 0.50
open ⚖ 1500
What is optimal treatment timing?
📑 0.50 💥 0.50
open ⚖ 1500
What are the genetic variants affecting ZIP11 function?
📑 0.50 💥 0.50
open ⚖ 1500
Why are females less severely affected?
📑 0.50 💥 0.50
open ⚖ 1500
Can ZIP11 be targeted therapeutically?
📑 0.50 💥 0.50
open ⚖ 1500
Can we develop mutation-specific therapies?
📑 0.50 💥 0.50
open ⚖ 1500
Temporal dynamics**: When does RhoA dysregulation begin in disease?
📑 0.50 💥 0.50
open ⚖ 1500
Substrate-specific inhibition
📑 0.50 💥 0.50
open ⚖ 1500
Gene therapy
📑 0.50 💥 0.50
open ⚖ 1500
Combination approaches
📑 0.50 💥 0.50
open ⚖ 1500
Therapeutic targeting**: Can selective modulation be achieved?
📑 0.50 💥 0.50
open ⚖ 1500
How can we exploit H3K27M for glioma therapy?
📑 0.50 💥 0.50
open ⚖ 1500
What determines the different phenotypic outcomes of H3F3B vs H3F3A mutations?
📑 0.50 💥 0.50
open ⚖ 1500
Biomarkers**: Can RAB7L1 expression serve as a disease biomarker?
📑 0.50 💥 0.50
open ⚖ 1500
Therapeutic targeting**: Can RAB7L1 activity be pharmacologically modulated?
📑 0.50 💥 0.50
open ⚖ 1500
Mechanism of GWAS variants**: How do risk variants affect RAB7L1 expression?
📑 0.50 💥 0.50
open ⚖ 1500
LRRK2-RAB7L1 axis**: What is the precise phosphorylation site and downstream effect?
📑 0.50 💥 0.50
open ⚖ 1500
Channel oligomerization**: Does TRPA1 form heteromers with other TRP channels in neurons, and does this affect pharmacology?
📑 0.50 💥 0.50
open ⚖ 1500
Isoform specificity**: What distinguishes CALM4 from other isoforms?
📑 0.50 💥 0.50
open ⚖ 1500
How does H3.3 specifically contribute to neuronal function?
📑 0.50 💥 0.50
open ⚖ 1500
Biomarker potential**: Could TRPA1 activity or expression serve as a biomarker for neuropathic pain or neurodegeneration?
📑 0.50 💥 0.50
open ⚖ 1500
Combination therapies**: Could TRPA1 antagonists be combined with disease-modifying approaches (anti-Aβ, anti-αSyn) for synergistic benefit in AD/PD?
📑 0.50 💥 0.50
open ⚖ 1500
Species differences in pharmacology**: Why do many rodent TRPA1 antagonists fail in human trials? What structural differences underlie this?
📑 0.50 💥 0.50
open ⚖ 1500
Cell-type specificity**: How do TRPA1 functions differ between sensory neurons, CNS neurons, microglia, and astrocytes?
📑 0.50 💥 0.50
open ⚖ 1500
Dual roles in protection vs. damage**: TRPA1 can be both neuroprotective (promoting damage clearance) and neurodestructive (driving calcium overload). What determines the outcome?
📑 0.50 💥 0.50
open ⚖ 1500
Can subunit-selective modulators provide therapeutic benefit without side effects?
📑 0.50 💥 0.50
open ⚖ 1500
What are the best targets for neuroprotective therapies?
📑 0.50 💥 0.50
open ⚖ 1500
How do specific NMDA receptor subtypes contribute to different brain functions?
📑 0.50 💥 0.50
open ⚖ 1500
Epigenetic Therapy
📑 0.50 💥 0.50
open ⚖ 1500
Clinical Translation
📑 0.50 💥 0.50
open ⚖ 1500
Can selective JNK2 inhibition provide therapeutic benefit?
📑 0.50 💥 0.50
open ⚖ 1500
What determines JNK isoform specificity in vivo?
📑 0.50 💥 0.50
open ⚖ 1500
Biomarker validation**: Is NPY5R a reliable disease marker?
📑 0.50 💥 0.50
open ⚖ 1500
Substrate identification
📑 0.50 💥 0.50
open ⚖ 1500
Can KDM5 modulation slow or reverse cognitive decline in AD models?
📑 0.50 💥 0.50
open ⚖ 1500
What is the role of KDM5D specifically (versus family members) in neuronal function?
📑 0.50 💥 0.50
open ⚖ 1500
Can selective KDM5 modulators be developed with acceptable brain penetration?
📑 0.50 💥 0.50
open ⚖ 1500
What are the precise neuronal targets of KDM5 family members in the brain?
📑 0.50 💥 0.50
open ⚖ 1500
Clinical translation
📑 0.50 💥 0.50
open ⚖ 1500
What is the precise molecular mechanism of MCC-mediated β-catenin degradation?
📑 0.50 💥 0.50
open ⚖ 1500
Gene editing
📑 0.50 💥 0.50
open ⚖ 1500
Systems biology
📑 0.50 💥 0.50
open ⚖ 1500
Mechanistic studies
📑 0.50 💥 0.50
open ⚖ 1500
Clinical translation
📑 0.50 💥 0.50
open ⚖ 1500
Cell-type specificity
📑 0.50 💥 0.50
open ⚖ 1500
Biomarker potential
📑 0.50 💥 0.50
open ⚖ 1500
Small molecule microtubule stabilizers
📑 0.50 💥 0.50
open ⚖ 1500
Combination strategies
📑 0.50 💥 0.50
open ⚖ 1500
Symptomatic management
📑 0.50 💥 0.50
open ⚖ 1500
Biomarker validation
📑 0.50 💥 0.50
open ⚖ 1500
Optogenetics
📑 0.50 💥 0.50
open ⚖ 1500
ADCY7-selective compounds
📑 0.50 💥 0.50
open ⚖ 1500
Crosstalk complexity
📑 0.50 💥 0.50
open ⚖ 1500
Human models
📑 0.50 💥 0.50
open ⚖ 1500
Gene therapy approaches
📑 0.50 💥 0.50
open ⚖ 1500
Therapeutic targeting
📑 0.50 💥 0.50
open ⚖ 1500
Single-cell analysis
📑 0.50 💥 0.50
open ⚖ 1500
Personalized medicine
📑 0.50 💥 0.50
open ⚖ 1500
Gene editing
📑 0.50 💥 0.50
open ⚖ 1500
Combination therapies
📑 0.50 💥 0.50
open ⚖ 1500
Patient-specific models
📑 0.50 💥 0.50
open ⚖ 1500
Structure-function relationships
📑 0.50 💥 0.50
open ⚖ 1500
Cell-type specificity
📑 0.50 💥 0.50
open ⚖ 1500
Compensatory mechanisms
📑 0.50 💥 0.50
open ⚖ 1500
Biomarker validation
📑 0.50 💥 0.50
open ⚖ 1500
Translation enhancers
📑 0.50 💥 0.50
open ⚖ 1500
Ribosome stabilizers
📑 0.50 💥 0.50
open ⚖ 1500
Gene therapy
📑 0.50 💥 0.50
open ⚖ 1500
Antisense oligonucleotides
📑 0.50 💥 0.50
open ⚖ 1500
Cell-type specificity
📑 0.50 💥 0.50
open ⚖ 1500
Therapeutic window
📑 0.50 💥 0.50
open ⚖ 1500
Therapeutic development
📑 0.50 💥 0.50
open ⚖ 1500
Cell-type specificity
📑 0.50 💥 0.50
open ⚖ 1500
Therapeutic window
📑 0.50 💥 0.50
open ⚖ 1500
Spatial transcriptomics
📑 0.50 💥 0.50
open ⚖ 1500
Systems biology
📑 0.50 💥 0.50
open ⚖ 1500
Understand genotype-phenotype correlations
📑 0.50 💥 0.50
open ⚖ 1500
Develop biomarkers
📑 0.50 💥 0.50
open ⚖ 1500
RNA targeting
📑 0.50 💥 0.50
open ⚖ 1500
Protein-protein interaction inhibitors
📑 0.50 💥 0.50
open ⚖ 1500
Cell replacement therapies
📑 0.50 💥 0.50
open ⚖ 1500
Aggregation mechanisms
📑 0.50 💥 0.50
open ⚖ 1500
Mechanism elucidation
📑 0.50 💥 0.50
open ⚖ 1500
Combined approaches
📑 0.50 💥 0.50
open ⚖ 1500
Natural history studies
📑 0.50 💥 0.50
open ⚖ 1500
Therapeutic trials
📑 0.50 💥 0.50
open ⚖ 1500
Biomarker Development
📑 0.50 💥 0.50
open ⚖ 1500
Population Studies
📑 0.50 💥 0.50
open ⚖ 1500
Biomarker validation**: Can STMN1 be clinically useful?
📑 0.50 💥 0.50

🌱 Cross-Pollination

Fields that illuminate Genes through bridging wiki connections. See all cross-field connections →

Cross-pollination from Companies 859 bridges →
Cross-pollination from Therapeutics 947 bridges →
Cross-pollination from Experiments 1,139 bridges →
Open Questions | Part of the SciDEX Atlas layer | API | Cross-field map